We would love to hear your thoughts about our site and services, please take our survey here.
Hot off the press, €8.1m awarded to PDC , so hopefully Genflow's next on the list.
https://www.businesswire.com/news/home/20240117630349/en/PDC*line-Pharma-and-Partners-Receive-%E2%82%AC8.1M-From-Walloon-Region-and-Wallonia-Health-Cluster-BioWin-for-Personalized-Therapeutic-Vaccine-Project
Thanks for posting it from the Telegram group ( I'm not a member) all very encouraging for the delivery of some very good news.
0 0 0
Eric confirmed in his August/September interview that Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of their R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans highly likely. Gl :-)
Nice on Northeast, a great find and thanks for posting. Excitement building. Gl :-)
The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.
In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.
Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.
Ps the Estee Lauder connection is very interesting and potentially very exciting considering Genflow's GF-3001 for Werner Syndrome ( premature ageing disease ) is a Topical delivery of Sirt6 directly to the skin, and so endless opportunities and potential in all aspects of age reversal. Gla :-)
Cheers Northeast, anytime now and hopefully the start of a great year ahead for all invested as positive newsflow is delivered, and yes indeed Porter, any association with Estee Lauder's longevity aspirations involving Sirtuin R&D can only be a good thing for Genflow going forward. C'mon Eric , ready when you are!!! ;-)
Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)
From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.
Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.
Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.
Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.
The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.
It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.
“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
https://cosmeticsbusiness.com/est%C3%A9e-lauder-targets-age-reversal-with-stanford-center
The Future Is Bright
To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.
Fortunately, the future’s looking bright with medical biotechnological advancements.
Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.
These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.
hTtps://genflowbio.com/premature-aging/
GenFlow Biosciences
1,399 followers
1h
At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF), we're passionate about unveiling the mysteries of aging. Our latest article dives deep into premature aging, offering valuable insights on how your lifestyle choices and genetic factors play a crucial role. Learn about the impacts on various body systems and get expert tips for staying youthful and healthy.
Read it here: htTps://loom.ly/565AscQ
#longevity #aging #healthspan
GenFlow Biosciences
1,399 followers
21h
In Sardinia, GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging in humans. Investigating its causes offers valuable insights into the aging process and may lead to strategies that enhance overall health and longevity.
Learn more about Werner here:
htTps://loom.ly/RcDWpwk #Werner #longevity #aging #healthspan
The date in the URL link below is November 2023, no doubt following the news of the appointment of the Joint Broker, and as good news could drop at anytime , it looks like there's going to be plenty of UPward momentum in sp in anticipation...Excitement building!!! Gl ;-)
Genflow Corporate Power Point Presentation
hTtps://genflowbio.com/wp-content/uploads/2023/11/GENF.corporate.US_.v1sm.pdf
The FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an announcement of a JV Veterinary partner. Gla ;-)
29/11/3
A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.
Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.
The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.
hTtps://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php
Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)
Looking good and strong with news expected soon, which could add significant value. Gla holders :-)
GenFlow Biosciences
1,386 followers
13h
Investing in GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) offers a unique opportunity to support pioneering work in the longevity field. Our company focuses on developing novel therapeutics that target the aging process, including our lead compound GF-1002, which is based on a centenarian variant of the SIRT6 gene. This innovative approach aims to extend both healthspan and lifespan, addressing the global challenge of aging and its associated health and economic impacts.
Learn more here: hTtps://loom.ly/MeQymHs
#GENF #longevity #healthspan #SIRT6
Cheers Porter, and full market interest can't be far off Northeast, and I'm sure Eric is ready to deliver a flow of positive news....the Biotech sector at long last could be ready for some serious UPside and market appreciation, judging by today's Top risers board and Genflow's tiny market offers tremendous UPside potential. Gl :-)
The Gaurdian....Company to Watch 2024!!!
4th January 2024
Genflow Biosciences
Longevity is not just for billionaires, says Dr Eric Leire, the founder and chief executive of Genflow Biosciences, which in December 2022 became the first anti-ageing biotech to list in Europe.
The London-listed and headquartered company, which has its labs in Belgium and an office in Cambridge, Massachusetts, is developing gene therapies for longer, healthier lives.
The company’s work is based on a rare mutation of the SIRT6 gene found in people who live beyond the age of 100, which was discovered by Dr Vera Gorbunova’s team at the University of Rochester in 2019. She chairs Genflow’s scientific advisory board.
“Some people are lucky to have the good gene, and what we want to do is share that luck with everybody,” says Leire, who previously worked for Pfizer and Schering-Plough.
Genflow plans to test an experimental therapy on people with an age-related liver disease called NASH in early 2025. It is also developing a therapy for Werner syndrome, a rare accelerated ageing disease, by which SIRT6 messenger RNA delivers the gene to the skin. Genflow is also launching a programme to prevent age-related loss of muscle mass, funded by new research grants.
It started trading on the OTCQB venture market in the US in the summer, to expand its reach to US investors. As an early-stage biotech, Genflow is a risky investment; its London-listed shares have lost nearly 90% of their value in the first year of trading. But it is certainly one to watch. The longevity science sector is forecast to reach $2bn (£1.6bn) by 2030, according to Insight Analytics. Julia Kollewe
Much more to come Porter...A very Bright and Happy New Year!!! :-)
0 0 0
GenFlow Biosciences
1,380 followers
3m
GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to be named "a firm to watch" by the The Guardian today.
As clinical trials for patients suffering from NASH get underway in 2025, we are very excited for 2024 and beyond.
Read the article here: hTtps://loom.ly/PWx_em8 #GENF #longevity #healthspan #SIRT6 #smallcaps #companytowatch
Get UP there!!! " A Bright New Year " ahead, with any Luck. In Eric we trust!!! ;-)
On and UP....it's been a while, hopefully in anticipation of a flow of imminent good news along with a significant re-rate or two....C'mon Eric....Gla holders..:-)